IMMEDIATE study
Completed
- Conditions
- - idiopathic inflammatory myopathies- myositis (practical/clinical synonym)- auto-immune disease- neuromuscular disease
- Registration Number
- NL-OMON25293
- Lead Sponsor
- Department of Neurology, Academic Medical Center Amsterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
•Adult patients (age ≥ 18 years)
•Treatment naïve patients
Exclusion Criteria
•IVIg treatment related:
oSubjects who have received clinical relevant immunosuppressive medication (e.g. plasmapheresis, biologicals, immune therapy etc.) within the last 6 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objective is to determine the number of participants with clinical significant improvement (ACR/EULAR Total Improvement Score (TIS) of at least 40) at 9 weeks after start of IVIg treatment.
- Secondary Outcome Measures
Name Time Method